For Canada specifically, and in our guidance, as we said in prior quarters, that SEMA LOE in international markets will impact group sales by low single digits. Canada is the biggest contributor And of course, we put in assumptions around timing of generic launches, approvals and launches. We don't have detailed insights into the status of those files and remediation of these notices of deficiencies. But obviously, time is a key variable in terms of impact. I think the direction of travel is the same. But that could be both an upside and a downside to our guidance, depending on the pace of approval of generics in Canada. So it remains to be seen.

Feb 4, 2026 / receipt, needs a key / Karsten, CFO | earnings call 2026-02-04 | transcript cdd14653-09fd-45b8-a5a7-5bef7d5e9b21 | chars 55651-56305 | segment 57